Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.31 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18044479 | 1.00 | PTGS2 (0.40) | PTGS2PTGS1HSD17B10LMNAUSP2 | |
| SCHEMBL27206706 | 1.00 | PTGS2 (0.40) | PTGS2PTGS1HSD17B10LMNAUSP2 | |
| SCHEMBL28404512 | 1.00 | PTGS2 (0.40) | PTGS2PTGS1HSD17B10LMNAUSP2 | |
| SCHEMBL23212122 | 0.99 | PTGS2 (0.41) | PTGS2PTGS1HSD17B10LMNAUSP2 | |
| SCHEMBL516227 | 0.94 | TAAR1 (0.36) | PTGS2PTGS1HSD17B10LMNAGAA | |
| SCHEMBL29488092 | 0.94 | TAAR1 (0.36) | PTGS2PTGS1HSD17B10LMNAGAA | |
| SCHEMBL478439 | 0.94 | TAAR1 (0.36) | PTGS2PTGS1HSD17B10LMNAGAA | |
| SCHEMBL29790344 | 0.94 | TAAR1 (0.36) | PTGS2PTGS1HSD17B10LMNAGAA | |
| SCHEMBL1648239 | 0.93 | GAA (0.36) | PTGS2PTGS1HSD17B10GAATAAR1 | |
| SCHEMBL600568 | 0.90 | PTGS2 (0.35) | PTGS2PTGS1HSD17B10LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10729782-B2 | Antibody-drug conjugate produced by binding through linker having hydrophilic structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2910573-B1 | ANTIBODY-DRUG CONJUGATE PRODUCED BY BINDING THROUGH LINKER HAVING HYDROPHILIC STRUCTURE | DAIICHI SANKYO CO LTD (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-20180071403-A1 | ANTIBODY-DRUG CONJUGATE PRODUCED BY BINDING THROUGH LINKER HAVING HYDROPHILIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-03-15 | — | — | US | disclosed |
| US-9872924-B2 | Antibody-drug conjugate produced by binding through linker having hydrophilic structure | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-01-23 | — | — | US | disclosed |
| EP-2910573-A1 | ANTIBODY-DRUG CONJUGATE PRODUCED BY BINDING THROUGH LINKER HAVING HYDROPHILIC STRUCTURE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10729782-B2 | Antibody-drug conjugate produced by binding through linker having hydrophilic structure | LANCL2, TLL1, LANCL1 | PTGS2 3486/4885PTGS1 2828/4885HSD17B10 2009/4885 |
| US-20180071403-A1 | ANTIBODY-DRUG CONJUGATE PRODUCED BY BINDING THROUGH LINKER HAVING HYDROPHILIC STRUCTURE | LANCL2, TLL1, LANCL1 | PTGS2 3486/4885PTGS1 2828/4885HSD17B10 2009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.